Search Results - marc+rothenberg

4 Results Sort By:
IL-13 Induced Gene Signature for Eosinophilic Esophagitis
IL-13 Induced Gene Signature for Eosinophilic Esophagitis (CHMC Ref. Id: 2007-0811) Overview: Eosinophilic esophagitis (EE) is an emerging worldwide disease. The current treatment for EE is with swallowed glucocorticoids, however, only a subset of EE patients experience remission from the disease following treatment with topical steroids. Dr....
Published: 8/20/2018   |   Inventor(s): Marc Rothenberg
Keywords(s): 1 - Diagnostic, Diagnostic Tests, Genomics/Epigenomics, Inflammation/Immunity/Immune Therapy
Category(s): Diagnostics
Diagnostic Classification of Esophagitis
Diagnostic Classificiation of Esophagitis (CHMC Ref. Id: 2005-0401) Overview: Eosinophilic esophagitis (EoE) is an emerging worldwide disease and growing health problem. The primary symptoms of EoE (chest and abdominal pain, dysphagia, heartburn, vomiting, and food impaction) are also observed in patients with chronic esophagitis (CE), including...
Published: 5/16/2024   |   Inventor(s): Marc Rothenberg
Keywords(s): 1 - Diagnostic, Diagnostic Tests, Genomics/Epigenomics, Inflammation/Immunity/Immune Therapy
Category(s): Diagnostics
Critical Role for Eotaxin-3 in Eosinophilic Esophagitis
Critical Role for Eotaxin-3 in Eosinophilic Esophagitis (CHMC Ref. Id: 2004-1003) Overview: Eosinophilic esophagitis (EE) is often confused with gastroesophageal reflux disease (GERD), but it does not typically respond to anti-GERD therapy. Patients with EE typically have elevated levels of eosinophilis in their esophageal tissue and diagnosis...
Published: 5/16/2024   |   Inventor(s): Marc Rothenberg
Keywords(s): Diagnostic Tests, Genomics/Epigenomics, Inflammation/Immunity/Immune Therapy
Category(s): Therapeutics
Pharmaceutical Targeting of Eosinophils by CCR-3 Mediated Internalization
Pharmaceutical Targeting of Eosinophils by CCR-3 Medicated Internalization (CHMC Ref. Id: 1999-0210) Overview: Eosinophils normally appear in peripheral blood at a concentration of ~1-3% of total leukocytes and their presence in tissue is primarily restricted to the mucosa. However, in various disease states, such as eosinophilic esophagitis (EoE),...
Published: 8/23/2021   |   Inventor(s): Marc Rothenberg, Nives Zimmermann
Keywords(s): 1 - Therapeutic
Category(s): Therapeutics